Clinical trial
A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured With Recombinant Human Albumin (rHA) Versus V205C Manufactured With Pooled-Donor Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age
NCT00092404 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured With Recombinant Human Albumin (rHA) Versus V205C Manufactured With Pooled-Donor Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2001
- Completion date
- June 30, 2005
- Enrollment
- 1,210 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.